Cellectis S.A.
CLLS
$1.53
$0.021.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4,393.29% | 10,351.61% | 4,428.65% | 3,157.55% | -98.23% |
| Total Other Revenue | 43.47% | 24.31% | -20.90% | -42.40% | 31.51% |
| Total Revenue | 662.06% | 997.99% | 374.91% | 82.58% | -88.51% |
| Cost of Revenue | -- | -- | -- | -- | 6.66% |
| Gross Profit | 1,110.30% | 997.99% | 374.91% | 82.58% | -92.47% |
| SG&A Expenses | 5.59% | 60.12% | -1.72% | 2.82% | 175.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -93.32% | -1,558.33% | -29.92% | -131.53% | 196.70% |
| Total Operating Expenses | -16.81% | 29.16% | 4.26% | 3.41% | 34.53% |
| Operating Income | 63.27% | 47.90% | 27.14% | 8.88% | -403.78% |
| Income Before Tax | 115.40% | -33.03% | 13.59% | 119.33% | -62.44% |
| Income Tax Expenses | 8,466.67% | -155.66% | -174.81% | -- | -93.10% |
| Earnings from Continuing Operations | 114.17% | -31.88% | 14.98% | 120.27% | -61.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -100.00% |
| Net Income | 114.17% | -31.88% | -115.85% | 118.76% | -55.88% |
| EBIT | 63.27% | 47.90% | 27.14% | 8.88% | -403.78% |
| EBITDA | 71.79% | 55.99% | 31.63% | 10.53% | -960.80% |
| EPS Basic | 109.24% | 26.77% | -33.52% | 113.45% | -9.09% |
| Normalized Basic EPS | 110.53% | 51.82% | 27.00% | 116.46% | -3.73% |
| EPS Diluted | 108.85% | 26.77% | -33.52% | 74.34% | -8.55% |
| Normalized Diluted EPS | 110.53% | 51.82% | 27.00% | 111.46% | -3.73% |
| Average Basic Shares Outstanding | 53.44% | 80.08% | 61.65% | 39.57% | 42.89% |
| Average Diluted Shares Outstanding | 53.44% | 80.08% | 61.65% | 100.37% | 42.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |